This paper presents the final findings from the extended phase of a clinical trial called CHAMPION MG, investigating the long-term effectiveness and safety of ravulizumab for adults with a specific type of myasthenia gravis characterized by antibodies against the acetylcholine receptor. The study followed patients for up to four years, including those who initially received ravulizumab and those who switched from placebo to ravulizumab. Results indicated sustained improvements in various measures of disease activity and quality of life for patients treated with ravulizumab. The research also highlights a significant reduction in corticosteroid use and clinical deterioration events among patients receiving the treatment, with no new safety concerns arising over the extended study period, including no reported cases of meningococcal infection.